Bluebird Bio
FDA Grants Priority Review to Bluebird Bio's Sickle Cell Disease Gene Therapy
The US Food and Drug Administration is expected to decide whether to approve lovotibeglogene autotemcel by Dec. 20.
The US Food and Drug Administration is expected to decide whether to approve lovotibeglogene autotemcel by Dec. 20.